



Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019

March 21, 2019

BRIDGEWATER, N.J., March 21, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 fourth quarter and full year financial results on Wednesday, March 27, 2019, after the close of the U.S. financial markets and provide a business and financial update.

Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:

| | |
|------------------|---------------------------|
| Date | Wednesday, March 27, 2019 |
| Time | 5:00 p.m. EDT |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |

Webcast (live and replay) www.osmotica.com under the "Investor & News" section

A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference call ID 2286829. The webcast will be archived for 30 days at the aforementioned URL.

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. Our diversified product portfolio in the specialty neurology and women's health therapeutic areas, together with our non-promoted complex formulations of generic drugs, form the foundation of our unwavering commitment to improve patients' lives.

Osmotica has a late-stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: arbaclofen extended-release tablets for spasticity in multiple sclerosis patients and RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.

Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com



Source: Osmotica Pharmaceuticals plc